As Sweden positions itself for long-term strength in life science, important questions arise: How do we build and scale companies here at home, what challenges are we facing, and what unique advantages does Sweden offer?

This session examines the structural strengths behind Sweden’s life science ecosystem — from world-class research environments to advanced manufacturing capabilities and a highly skilled workforce. Together, we explore what enables companies to grow from idea to global impact, and which strategic choices will matter most.

Welcome to the launch of the 2026 Life Science Barometer report. This year’s edition presents the state of the industry, national statistics, and an international perspective.

After several years marked by tight capital, valuation pressure, and hesitant public markets, the global sector continues to grapple with the effects of the “biotech winter.” As we look forward in 2026, a key question emerges: How can Swedish companies navigate the tail end of the biotech winter — and build companies capable of thriving toward 2030? 

This panel brings together investors and leading Swedish innovators in to unpack the signals, surprises, and strategic lessons from JPM 2026. What themes dominated investor conversations? Which types of companies attracted attention — and which struggled? Are we seeing early signs of recovery, or simply a new phase of the downturn?  

We wrap up this inspiring afternoon by handing out the SwedenBIO Award to reward a successful and exemplary member company that have distinguished themselves and contributed to positive attention for Swedish life science. Don’t miss out!